Cecilia Vellani
Dirigente medico

Richiedi appuntamento
Specializzazione
  • Medicina nucleare
Contatti
  • 0382.592403
  • [javascript protected email address]

Quarterly Journal Nucl Med Mol Imaging 2009 October;53(5):546-61. update on the diagnosis and treatment of differentiated thyroid cancer . Individualized dosimetry in the management of metastatic differentiated thyroid cancer .Chiesa C, Castellani M. R., Vellani C., Orunesu E, Negri A, Azzeroni R, Botta F, Maccauro M, Aliberti G, Seregni E, Lassmann M, Bombardieri E.

Quarterly Journal Nucl Med Mol Imaging. 2009 Oct;53(5):513-9. Redifferentiating agents in non-radioiodine avid cancer. Seregni E, Vellani C, Castellani MR, Maccauro M, Pallotti F; Scaramellini G, Guzzo M, Greco A,

Quarterly Journal Nucl Med Mol Imaging. 2010 Feb;54(1):84-91. treatment with tandem [(90)y]dota-tate and [(177)lu] dota-tate of neuroendocrine tumors refractory to conventional therapy: preliminary results. Seregni E, Maccauro M, Coliva A, Castellani MR, Bajetta E, Aliberti G, Vellani C, Chiesa C, Martinetti A, Bogni A, Bombardieri E.

Quarterly Journal of Nuclear Medicine and Molecular Imaging.‚ÄČ2013;57(2):146-152. Iodine-131 metaiodobenzylguanidine (I-31 MIBG) diagnosis and therapy of pheochromocytoma and paraganglioma: current problems, critical issues and presentation of a sample case. Castellani MR,  Aktolun C,  Buzzoni R,  Seregni E,  Chiesa C,  Maccauro M, Aliberti G.L,  Vellani C, Lorenzoni A, Bombardieri E

 

Presta servizio in queste sedi

Profili simili


GH4T12Fv7resHnpU